RBC Capita Affirms XOMA (XOMA) at 'Sector Perform'; Gevokizumab Sale Could Bring in More non-Dilutive Cash
Tweet Send to a Friend
RBC Capita affirms XOMA Corporation (Nasdaq: XOMA) with a Sector Perform rating and $2 price target following Q4 results and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
